FRLN News and Press, Freeline Therapeutics Holdings plc From 04/04/23

2023-04-04 10:31:02 ET Freeline Therapeutics Holdings plc (FRLN) Q4 2022 Earnings Conference Call April 4, 2023 8:00 A.M. ET Company Participants Naomi Aoki - Senior Vice President, Head of Investor Relations & Corporate Communications Michael Parini - Chief Exec...

2023-04-04 07:46:33 ET Freeline Therapeutics ( NASDAQ: FRLN ) signed a patent and know-how license deal with Forcefield Therapeutics. Under the agreement, Freeline gains rights to develop and commercialize AAV gene therapies for certain heart conditions using key targets ident...

2023-04-04 07:02:46 ET Freeline Therapeutics press release ( NASDAQ: FRLN ): FY GAAP EPS of -$1.50 beats by $0.28 . As of December 31, 2022, unrestricted cash and cash equivalents were $47.3 million, compared to $117.7 million as of December 31, 2021. For further...

Prioritizing development of FLT201, a potential first- and best-in-class gene therapy for most common type of Gaucher disease Initial clinical data on FLT201 expected in Q3 2023 Restructuring organization and pausing development of FLT190 to extend cash runway into Q2 2024 ...

LONDON, March 28, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that it will host a live conference call and webcast at 8:00 a.m. ET on Tuesday, April 4, 2023 to report its full year 2022 financial results and provide a corporate update. To ...

Please find enclosed the presentation of Frontline plc´s fourth quarter 2022 results to be held on the webcast / conference call 28 February, 2023 at 15:00 CET. This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act ...

FRONTLINE PLC REPORTS RESULTS FOR THE FOURTH QUARTER ENDED DECEMBER 31, 2022 Frontline plc (the “Company” or “Frontline”), today reported unaudited results for the three and twelve months ended December 31, 2022: Highlights Highest quarter...

Sangamo Therapeutics ( NASDAQ: SGMO ) added ~11% on Monday after Wedbush Securities upgraded the genomic medicine company to Outperform from Neutral, noting a recent data readout for the company's Fabry disease candidate ST-920. Announcing updated data from its Phase 1/2 STAAR cli...

Frontline plc’s preliminary fourth quarter 2022 results will be released on Tuesday February 28, 2023, and a webcast and conference call will be held at 3:00 p.m. CET (9:00 a.m. U.S. Eastern Time). The results presentation will be available for download from the Investor Relations section ...

LONDON, Feb. 10, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the closing of the previously announced sale of its CMC-focused German subsidiary, Freeline Therapeutics GmbH, along with certain related intellectual property, to Ascend Gene and Cell ...